In this study, we found that GA can not only alleviate bleomycin-induced pulmonary fibrosis in in vivo but also inhibit the EMT process and the main mechanism may be related to the regulation of CF modification of TGF-βR and WNT, and affect the key protein in the TGF-β/Smad2/3 and WNT/β-catenin signaling pathways. The gene discussed is SMAD2; the disease is pulmonary fibrosis.